Novo Nordisk AS (OCSE:NOVO B)
kr 775.8 18.5 (2.44%) Market Cap: 3.45 Til Enterprise Value: 3.43 Til PE Ratio: 36.59 PB Ratio: 28.65 GF Score: 97/100

Q1 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript

May 06, 2021 / 11:00AM GMT
Release Date Price: kr227.8 (-0.79%)
Operator

Hello and welcome to the Q1 2021 Novo Nordisk A/S Earnings Presentation. (Operator Instructions) Today, I'm pleased to present Karsten Munk Knudsen. Please go ahead with your meeting.

Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board

/- -

Thank you, and welcome to the Q1 results meeting for Novo Nordisk. Today with me, I have Camilla Sylvest, Head of Commercial Strategy; and Martin Lange, Head of Global Development. So before moving into our investor presentation, I'd just like to thank Keyur Parekh and Goldman Sachs for orchestrating this London lunch conference meeting. We had been looking forward to meeting you all in person as we did a year ago. And hopefully, we'll be getting closer to meeting in-person in coming quarters.

So we'll -- the process for this meeting is that we'll do a quick review of our quarterly slide deck. It'll last to the tune of 15 minutes, after which we will be moving on to a Q&A session.

So -- and as you know, the statements we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot